Drug Profile


Alternative Names: INCB-024360; INCB-24360

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Incyte Corporation
  • Developer Bristol-Myers Squibb; Genentech; Immunovaccine; Incyte Corporation; MedImmune; Merck AG
  • Class Amides; Antineoplastics; Imides; Oxadiazoles; Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Phase I/II Colorectal cancer; Glioblastoma; Head and neck cancer
  • Phase I Urogenital cancer
  • Preclinical Pancreatic cancer

Most Recent Events

  • 09 Sep 2017 Updated safety and efficacy data from the phase I/II ECHO-202 trial in Solid tumours (advanced melanoma cohort) released by Incyte Corporation
  • 30 Aug 2017 Safety and efficacy data from the phase I/II ECHO-202 trial in Cancer (Advanced melanoma cohort) released by Incyte Corporation
  • 23 Aug 2017 Masonic Cancer Center, University of Minnesota in collaboration with Incyte completes a phase I trial in Ovarian, Fallopian tube and Peritoneal cancer (Combination therapy, Second-line therapy) in the USA (NCT02118285)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top